Evotec And Arix Bridge Gap With Latest Cancer Funding

Arix Biosciences and Evotec AG have formed an academic partnership to accelerate research discoveries at the Fred Hutchison Cancer Research Center.

SC1805_Golden Gate Bridge_136918865_1200.jpg

The German biotech Evotec AG is to use its BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) model, an integrated fund and reward model, to form a new partnership withArix BioSciences PLC, LAB591. Together with the Fred Hutchinson Cancer Research Center, the three partners will jointly select promising research projects from the laboratories of the cancer research center, which is based in Seattle. The initial term of LAB591 is five years.

Once a research project has been chosen, Evotec will collaborate with Fred Hutchison on the research, seed-funded by Arix. Depending...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from R&D

  • ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

     
    • By 

    The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

More from Scrip